Expression of p57kip2 in germ cells and Leydig cells in human testis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Sung-Tae | - |
dc.contributor.author | Park, Nam-Cheol | - |
dc.contributor.author | Yi, Lee S. H. | - |
dc.contributor.author | Gye, Myung Chan | - |
dc.date.accessioned | 2022-12-21T09:56:42Z | - |
dc.date.available | 2022-12-21T09:56:42Z | - |
dc.date.created | 2022-09-16 | - |
dc.date.issued | 2006-11 | - |
dc.identifier.issn | 0148-5016 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/180787 | - |
dc.description.abstract | p57(kip2), a KIP family cyclin-dependent kinase (Cdk) inhibitor, blocks the cell cycle by acting on multiple cyclin-Cdk complexes. To investigate the role of p57(kip2) in human fertility, the expression of p57(kip2) was investigated in testes from normal and obstructive azoospermic male patients who were positive for p57(kip2) mRNA. In the seminiferous tubule, strong immunoreactivity of p57(kip2) was found in nuclei of early spermatocytes, but not in the spermatogonia. The p57(kip2) immunoreactivity in spermatocytes was markedly heterogeneous. Preleptotene spermatocytes showed strong p57(kip2) immunoreactivity, but no visible signal was found in late pachytene spermatocytes. Nuclei of the elongating spermatids was also positive for p57(kip2) immunoreactivity. Taken together, this suggests that p57(kip2) may play a role in the regulation of meiotic progression of early spermatocytes and cell cycle arrest and differentiation of spermatids. p57(kip2) immunoreactivity was found in the perinuclear region of the peritubular cells, but not in the Sertoli cells. In Leydig cells, moderate immunoreactivity of p57(kip2) was largely found in the cytoplasm, suggesting the noble function of p57(kip2) in the differentiation of adult Leydig cells. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | TAYLOR & FRANCIS INC | - |
dc.title | Expression of p57kip2 in germ cells and Leydig cells in human testis | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Gye, Myung Chan | - |
dc.identifier.doi | 10.1080/01485010600822903 | - |
dc.identifier.scopusid | 2-s2.0-33749536074 | - |
dc.identifier.wosid | 000241055900009 | - |
dc.identifier.bibliographicCitation | ARCHIVES OF ANDROLOGY, v.52, no.6, pp.463 - 469 | - |
dc.relation.isPartOf | ARCHIVES OF ANDROLOGY | - |
dc.citation.title | ARCHIVES OF ANDROLOGY | - |
dc.citation.volume | 52 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 463 | - |
dc.citation.endPage | 469 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Endocrinology & Metabolism | - |
dc.relation.journalWebOfScienceCategory | Andrology | - |
dc.subject.keywordPlus | DEPENDENT KINASE INHIBITOR | - |
dc.subject.keywordPlus | CDK INHIBITOR | - |
dc.subject.keywordPlus | MOUSE DEVELOPMENT | - |
dc.subject.keywordPlus | P57(KIP2) | - |
dc.subject.keywordPlus | MEIOSIS | - |
dc.subject.keywordPlus | DIFFERENTIATION | - |
dc.subject.keywordPlus | PROLIFERATION | - |
dc.subject.keywordPlus | P27(KIP1) | - |
dc.subject.keywordPlus | UNIQUE | - |
dc.subject.keywordPlus | GENE | - |
dc.subject.keywordAuthor | germ cells | - |
dc.subject.keywordAuthor | Leydig cells | - |
dc.subject.keywordAuthor | p57(kip2) | - |
dc.subject.keywordAuthor | testis | - |
dc.subject.keywordAuthor | human | - |
dc.identifier.url | https://www.tandfonline.com/doi/full/10.1080/01485010600822903 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.